CONSHOHOCKEN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 10:45 A.M. ET.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
PALO ALTO--(BUSINESS WIRE)--DLA Piper has welcomed Josh Seidenfeld as Chair of the firm’s Northern California…
PALO ALTO--(BUSINESS WIRE)--DLA Piper has welcomed Josh Seidenfeld as Chair of the firm’s Northern California…
First worldwide Allia Moveo installation at Hôpital Marie-Lannelongue in France highlights progress in redefining interventional…
First worldwide Allia Moveo installation at Hôpital Marie-Lannelongue in France highlights progress in redefining interventional…
Available at no additional cost, Dandy Cart turns scans into clear, visual stories, driving stronger…
Winter Park, Florida--(Newsfile Corp. - February 2, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a…